Recently, rucaparib has been tested as single agent or in combination with the antimetabolite 5-fluoro-Uracile (5FU) in vitro (DNMT3A mut OCI-AML2 and T-ALL RPMI-8402 cells) and in vivo in AML (mice transplanted with KMT2A-MLLT3 AML primary cells) and ALL (mice transplanted with pre-T-ALL primary cells) showing elevated efficacy [110]. Here, DNMT3A is linked to acute lymphoblastic leukemia.